We are live on ! Find out more
BLRX icon

BioLineRX

18 hedge funds and large institutions have $3.37M invested in BioLineRX in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.86% less ownership

Funds ownership: 18.15% → 9.29% (-8.9%)

36% less funds holding

Funds holding: 28 → 18 (-10)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

96% less capital inflows, than outflows

Capital inflows: $216K | Capital outflows: $4.86M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
18
Holders Change
-10
Holders Change %
-35.71%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
3
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLRX Hedge Fund Activity: Q4 2022 in Review

18 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2022, worth a combined $3.37M — down 67% from $10.3M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of BLRX and 2 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $141K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.59M sold.

  • 18 institutional investors held BioLineRX (BLRX) as of Q4 2022, down from 28 in Q3 2022.
  • Funds reported $3.37M of BioLineRX stock for Q4 2022, down 67% quarter-over-quarter.
  • 2 funds opened new BioLineRX positions in Q4 2022 and 11 closed out, a net change of -9 holders.
  • The largest BioLineRX buyer in Q4 2022 was Renaissance Technologies, an estimated $141K added.
  • The largest BioLineRX seller in Q4 2022 was Armistice Capital, an estimated $2.59M sold.

Based on aggregated 13F filings for Q4 2022.